These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

188 related articles for article (PubMed ID: 9810213)

  • 41. Doping control analyses in horseracing: a clinician's guide.
    Wong JK; Wan TS
    Vet J; 2014 Apr; 200(1):8-16. PubMed ID: 24485918
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Possibility of enhanced risk of retinal angiogenesis in athletes with pre- existing retinal situation abusing erythropoietin doping: a hypothesis.
    Rastmanesh R
    Curr Drug Saf; 2012 Apr; 7(2):164-9. PubMed ID: 22873500
    [TBL] [Abstract][Full Text] [Related]  

  • 43. The straight dope.
    Peota C
    Minn Med; 2010 Dec; 93(12):14-6. PubMed ID: 21265411
    [No Abstract]   [Full Text] [Related]  

  • 44. Veterinary medicines and competition animals: the question of medication versus doping control.
    Toutain PL
    Handb Exp Pharmacol; 2010; (199):315-39. PubMed ID: 20204593
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Blood transfusion in sports.
    Giraud S; Sottas PE; Robinson N; Saugy M
    Handb Exp Pharmacol; 2010; (195):295-304. PubMed ID: 20020370
    [TBL] [Abstract][Full Text] [Related]  

  • 46. DOPING. Cyclists' favorite drug falls flat in trial.
    Enserink M
    Science; 2016 Jul; 353(6296):206-7. PubMed ID: 27418482
    [No Abstract]   [Full Text] [Related]  

  • 47. A novel method utilising markers of altered erythropoiesis for the detection of recombinant human erythropoietin abuse in athletes.
    Parisotto R; Gore CJ; Emslie KR; Ashenden MJ; Brugnara C; Howe C; Martin DT; Trout GJ; Hahn AG
    Haematologica; 2000 Jun; 85(6):564-72. PubMed ID: 10870111
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Doping in sport.
    Davey G; Nerurkar R
    Lancet; 1998 Nov; 352(9142):1781-2. PubMed ID: 9848375
    [No Abstract]   [Full Text] [Related]  

  • 49. Sports haematology.
    Shaskey DJ; Green GA
    Sports Med; 2000 Jan; 29(1):27-38. PubMed ID: 10688281
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Testing for recombinant human erythropoietin in urine: problems associated with current anti-doping testing.
    Lundby C; Achman-Andersen NJ; Thomsen JJ; Norgaard AM; Robach P
    J Appl Physiol (1985); 2008 Aug; 105(2):417-9. PubMed ID: 18583375
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Haemoglobin, haematocrit and red blood cell indices in elite cyclists. Are the control values for blood testing valid?
    Schumacher YO; Grathwohl D; Barturen JM; Wollenweber M; Heinrich L; Schmid A; Huber G; Keul J
    Int J Sports Med; 2000 Jul; 21(5):380-5. PubMed ID: 10950450
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Altitude Training and Recombinant Human Erythropoietin: Considerations for Doping Detection.
    Sutehall S; Muniz-Pardos B; Lima G; Wang G; Malinsky FR; Bosch A; Zelenkova I; Tanisawa K; Pigozzi F; Borrione P; Pitsiladis Y
    Curr Sports Med Rep; 2019 Apr; 18(4):97-104. PubMed ID: 30969231
    [TBL] [Abstract][Full Text] [Related]  

  • 53. No proof for augmented arterial oxygen content as only factor influencing exercise capacity after Epo doping.
    Böning D; Maassen N; Pries A
    J Appl Physiol (1985); 2008 Dec; 105(6):1988; author reply 1989. PubMed ID: 19050342
    [No Abstract]   [Full Text] [Related]  

  • 54. Comparison of a restricted transfusion schedule with erythropoietin therapy versus a restricted transfusion schedule alone in very low birth weight premature infants.
    Birenbaum HJ; Pane MA; Helou SM; Starr KP
    South Med J; 2006 Oct; 99(10):1059-62. PubMed ID: 17100024
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Biochemistry, physiology, and complications of blood doping: facts and speculation.
    Lippi G; Franchini M; Salvagno GL; Guidi GC
    Crit Rev Clin Lab Sci; 2006; 43(4):349-91. PubMed ID: 16769597
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Rogue athletes and recombinant DNA technology: challenges for doping control.
    Azzazy HM; Mansour MM
    Analyst; 2007 Oct; 132(10):951-7. PubMed ID: 17893796
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Evaluation of immunoassays for the measurement of erythropoietin (EPO) as an indirect biomarker of recombinant human EPO misuse in sport.
    Abellan R; Ventura R; Pichini S; Remacha AF; Pascual JA; Pacifici R; Di Giovannandrea R; Zuccaro P; Segura J
    J Pharm Biomed Anal; 2004 Sep; 35(5):1169-77. PubMed ID: 15336362
    [TBL] [Abstract][Full Text] [Related]  

  • 58. A comparison of the physiological response to simulated altitude exposure and r-HuEpo administration.
    Ashenden MJ; Hahn AG; Martin DT; Logan P; Parisotto R; Gore CJ
    J Sports Sci; 2001 Nov; 19(11):831-7. PubMed ID: 11695504
    [TBL] [Abstract][Full Text] [Related]  

  • 59. A strategy to deter blood doping in sport.
    Ashenden MJ
    Haematologica; 2002 Mar; 87(3):225-32. PubMed ID: 11869930
    [No Abstract]   [Full Text] [Related]  

  • 60. Blood doping: Then and now. A narrative review of the history, science and efficacy of blood doping in elite sport.
    Atkinson TS; Kahn MJ
    Blood Rev; 2020 Jan; 39():100632. PubMed ID: 31645265
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.